# US 2025/0144135 A1 · Treatment of neurodegenerative disease with sodium chlorite

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144135 A1
- Document ID: US20250144135A1
- Status: Published application
- Kind: A1
- Application number: 19/011,989
- Filed: 2025-01-07
- Published: 2025-05-08
- Earliest claimed: 2015-11-02
- Assignees: Neuvivo, Inc.; The Regents of the University of California
- Applicants: Neuvivo, Inc.; The Regents of the University of California
- Inventors: Vernon A. NORVIEL; Michael S. McGrath
- Web page: https://patentgrep.com/patent/US20250144135A1

## CPC

- A61K 33/20: Elemental chlorine; Inorganic compounds releasing chlorine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method of treating frontotemporal dementia, or a childhood genetic neurodegenerative disease such as Ataxia Telangiectasia (A-T), or neurodegenerative diseases such as Parkinson's disease or neuropsychiatric diseases comprising administering to a subject in need thereof an effective amount of chlorite composition, such as sodium chlorite. The present invention thereby provides a method of modulating the immune system in a subject in need thereof. Described herein are methods of administration and treatment.

## Claims

### Claim 1

A method comprising:
a) administering to a subject who has dementia a regimen of an amount of a compound that is therapeutically-effective for the dementia; and
b) monitoring a plasma level of C-reactive protein in the subject during the regimen and determining based on the monitoring that the plasma level of C-reactive protein in the subject is at least 1125 ng/mL,
wherein in the subject, the compound is converted to hypochlorite and the hypochlorite is converted to a chloramine after interaction with taurine.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is converted to hypochlorite at a surface of a macrophage through interaction with heme-associated iron.

### Claim 3 (depends on 1)

The method of claim 1, wherein the amount of the compound that is therapeutically-effective for the dementia is about 1.5 mg/kg/day to about 3.5 mg/kg/day and the administering occurs on each of about five days over one week.

### Claim 4 (depends on 1)

The method of claim 1, wherein the amount of the compound that is therapeutically-effective for the dementia is about 2.0 mg/kg/day and the administering occurs on each of about five days over one week.

### Claim 5 (depends on 1)

The method of claim 1, wherein the amount of the compound that is therapeutically-effective for the dementia is about 2.7 mg/kg/day and the administering occurs on each of about five days over one week.

### Claim 6 (depends on 1)

The method of claim 1, wherein the administering is intravenous infusion.

### Claim 7 (depends on 1)

The method of claim 1, wherein the administering occurs over a period ranging from about 0.5 to about 4 hours.

### Claim 8 (depends on 1)

The method of claim 1, wherein the administering occurs over a period of about 0.5 hours.

### Claim 9 (depends on 1)

The method of claim 1, wherein the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL comprises detecting the C-reactive protein in a biological sample of the subject.

### Claim 10 (depends on 1)

The method of claim 1, wherein the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL comprises quantifying the C-reactive protein in a biological sample of the subject.

### Claim 11 (depends on 1)

The method of claim 1, wherein the dementia is Amyotrophic Lateral Sclerosis (ALS).

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 13 (depends on 1)

The method of claim 1, wherein the administering is by administration of a formulation, wherein the formulation comprises: a) the compound; and b) phosphate buffer, wherein the formulation has a pH of about 7 to about 11.

### Claim 14 (depends on 13)

The method of claim 13, wherein the pH is about 7.5.

### Claim 15 (depends on 1)

The method of claim 1, wherein the compound is a species of chlorite.

### Claim 16

A method of treating a dementia in a subject in need thereof, the method comprising:
a) administering to a subject who has dementia a regimen of an amount of a compound that is therapeutically-effective for the dementia; and
b) monitoring a plasma level of C-reactive protein in the subject during the regimen and determining based on the monitoring that the plasma level of C-reactive protein in the subject is at least 1125 ng/mL,
wherein in the subject, the compound is converted to hypochlorite and the hypochlorite is converted to a chloramine after interaction with taurine;
wherein the amount of the compound that is therapeutically-effective for the dementia is about 1.5 mg/kg/day to about 3.5 mg/kg/day and the administering occurs on each of about five days over one week;
wherein the administering is intravenous infusion;
wherein the administering occurs over a period ranging from about 0.5 to about 4 hours;
wherein the administering is by administration of a formulation, wherein the formulation comprises: a) the compound; and b) phosphate buffer, wherein the formulation has a pH of about 7 to about 9.5;
wherein the dementia is Amyotrophic Lateral Sclerosis (ALS);
wherein the determining that the subject has the plasma level of C-reactive protein that is at least 1125 ng/mL comprises quantifying the C-reactive protein in a biological sample of the subject; and
wherein the subject is human.

### Claim 17 (depends on 16)

The method of claim 16, wherein the compound is converted to hypochlorite at a surface of a macrophage through interaction with heme-associated iron.

### Claim 18 (depends on 16)

The method of claim 16, wherein the amount of the compound that is therapeutically-effective for the dementia is about 2.0 mg/kg/day and the administering occurs on each of about five days over one week.

### Claim 19 (depends on 16)

The method of claim 16, wherein the amount of the compound that is therapeutically-effective for the dementia is about 2.7 mg/kg/day and the administering occurs on each of about five days over one week.

### Claim 20 (depends on 16)

The method of claim 16, wherein the administering occurs over a period of about 0.5 hours.

### Claim 21 (depends on 16)

The method of claim 16, wherein the pH is about 7.5.

### Claim 22 (depends on 16)

The method of claim 16, wherein the compound is a species of chlorite.
